News Headlines

  1. CytoDyn Announces FDA Clearance To Proceed With Phase 2 Study Of Leronlimab (PRO 140) And Regorafenib As A Combination Therapy For Metastatic Colorectal Cancer

    CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has allowed a Phase 2 study to proceed for combination therapy of leronlimab and Regorafenib in patients with metastatic colorectal cancer (mCRC).

  2. Advarra Announces Intent to Acquire Forte, Market-Leading Provider of Clinical Technology Solutions

    The move strengthens the site-centric solutions portfolio of the largest global research compliance services organization

  3. Inventiva Achieves A Major Milestone By Completing Patient Recruitment For Its Phase IIb Clinical Study With Lanifibranor In NASH

    Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, recently announced the successful completion of patient recruitment for its Phase IIb NATIVE (NASH Trial to Validate IVA337 Efficacy) clinical trial evaluating lanifibranor, the Company’s lead product candidate, for the treatment of non-alcoholic steatohepatitis (NASH).

  4. Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration With Abbvie

    Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research-based biopharmaceutical company.

  5. Aduro Biotech Announces First Patient Dosed In Phase 2 Study Of ADU-S100 (MIW815) In Combination With KEYTRUDA® (pembrolizumab) For First-Line Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (HNSCC)

    Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the first patient has been dosed in a Phase 2 clinical trial of ADU-S100 (MIW815), a novel STING pathway activator, in combination with KEYTRUDA®(pembrolizumab), an approved anti-PD-1 antibody, as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

  6. uniQure Announces Achievement Of Planned Enrollment In HOPE-B Pivotal Trial Of AMT-061 (Etranacogene Dezaparvovec) In Patients With Hemophilia B

    uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, recently announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec (AMT-061), an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.

  7. Taconic Biosciences Participates In Second Rodent Research Reference Mission To The International Space Station

    Taconic Biosciences, a global leader in providing genetically engineered animal model solutions, announces its participation in the second Rodent Research Reference mission to the International Space Station.

  8. Quantum Genomics Announces Positive FDA Feedback On Phase III Program Design Of Firibastat In Resistant Arterial Hypertension

    Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant arterial hypertension and heart failure, today announced that it met a new milestone of its strategic plan by receiving favourable feedback from the U.S. Food and Drug Administration (FDA) regarding the Company’s Phase III development plan and trial design for firibastat in patients with resistant arterial hypertension.

  9. WCG Introduces Velos eResearch eXpress

    The WIRB-Copernicus Group®’s (WCG™) Clinical Services Division introduces Velos eResearch eXpress™, an out-of-the-box, cloud-based solution that enables clinical research sites to centralize and manage their research activities on a single, automated technology platform.

  10. UBC Announces Its New Version Of UBC Pathways™ Electronic Benefits Verification (eBV)

    UBC, a global leader of late-stage and patient support services, has broadened its electronic benefits verification system, which provides real-time benefit checks to the broadest reach of covered lives in the United States.